India  

Bharat Biotech

Indian biotechnology company and vaccine manufacturer

Bharat Biotech    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Bharat Biotech: Indian biotechnology company and vaccine manufacturer
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in Hyderabad, engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

0
shares
ShareTweetSavePostSend
 
BJP Minister Prakash Javadekar says India will be fully vaccinated by December 2021 | Oneindia News [Video]

BJP Minister Prakash Javadekar says India will be fully vaccinated by December 2021 | Oneindia News

Union Minister, BJP, Ministry of Environment, Forest and Climate Change, Ministry of Information and Broadcasting, Ministry of Heavy Industries and Public Enterprises, Congress leader, Congress MP,..

Credit: Oneindia     Duration: 02:01Published
Jharkhand Police: ₹ 35 lakh as fine from masses violating Covid norms  | Oneindia News [Video]

Jharkhand Police: ₹ 35 lakh as fine from masses violating Covid norms | Oneindia News

Thousands of people including Covid patients evacuated because of Cyclone Tauktae from Gujarat and Maharashtra; Bharat Biotech said that the company manufactured Covaxin is effective against the..

Credit: Oneindia     Duration: 03:39Published
Bharat Biotech responds to Delhi's Covaxin plea, says...|  Oneindia News [Video]

Bharat Biotech responds to Delhi's Covaxin plea, says...| Oneindia News

Covaxin's maker Bharat Biotech has refused to supply vaccine doses to Delhi, Deputy Chief Minister Manish Sisodia said today. Cong MP Rahul Gandhi hit out at the centre's push for positivity aid the..

Credit: Oneindia     Duration: 03:17Published

Chhattisgarh will receive 3.50 lakh doses of Covishield today [Video]

Chhattisgarh will receive 3.50 lakh doses of Covishield today

Health Minister of Chhattisgarh, TS Singh Deo on May 08 said the state government will receive 3.50 lakh doses of Covishield today and the further vaccination will go on with this. "We received 1.50..

Credit: ANI     Duration: 01:25Published
India receives first lot of Sputnik V vaccine [Video]

India receives first lot of Sputnik V vaccine

India on May 01 got the first lot of Russia's Sputnik V vaccine. The shipment arrived at the Hyderabad airport where Indian authorities received the first batch of 1.5 lakh doses of the Russia-made..

Credit: ANI     Duration: 02:00Published
Have asked for 67 lakh doses each from both vaccine manufacturing companies: CM Kejriwal [Video]

Have asked for 67 lakh doses each from both vaccine manufacturing companies: CM Kejriwal

Delhi Chief Minister Arvind Kejriwal informed that Delhi government has asked both vaccine manufacturing companies, Bharat Biotech and Serum Institute of India for 67 lakh doses each in next 3 months...

Credit: ANI     Duration: 01:50Published
Vaccine manufacturers will supply vaccine by May end: Jharkhand Health Minister [Video]

Vaccine manufacturers will supply vaccine by May end: Jharkhand Health Minister

Jharkhand Health Minister Banna Gupta on April 29 alleged that vaccine manufacturers said that they can deliver the vaccines only by May end. "We have ordered 25 lakh vaccines each from the Serum..

Credit: ANI     Duration: 01:44Published
After SII, Bharat Biotech reduces Covaxin price; Rs 400 per dose for state govts [Video]

After SII, Bharat Biotech reduces Covaxin price; Rs 400 per dose for state govts

Bharat Biotech on Thursday announced a cut in price of its COVID-19 vaccine 'Covaxin' it plans to sell to the states to Rs 400 per dose from the earlier Rs 600. This follows a widespread criticism of..

Credit: HT Digital Content     Duration: 01:25Published
Covid: SII reduces Covishield price, vaccine now at Rs 300 per dose for states [Video]

Covid: SII reduces Covishield price, vaccine now at Rs 300 per dose for states

Serum Institute of India reduced the vaccine price for the state government from Rs 400 per dose to Rs 300 per dose. SII chairman Adar Poonawalla announced on Twitter a reduction in prices...

Credit: HT Digital Content     Duration: 01:27Published
Phase-3 vaccination depends on availability of doses: Odisha govt [Video]

Phase-3 vaccination depends on availability of doses: Odisha govt

Even as the third phase of COVID-19 vaccination, which will cover people between the age group of 18 and 45, is starting from May 01, several states have expressed apprehensions over the availability..

Credit: ANI     Duration: 01:26Published
Centre asks Serum Institute, Bharat Biotech to lower Covid vaccines’ price [Video]

Centre asks Serum Institute, Bharat Biotech to lower Covid vaccines’ price

The central government on Monday asked the Serum Institute and Bharat Biotech to lower price of their COVID-19 vaccines amid criticism from various states who accused the companies of profiteering..

Credit: HT Digital Content     Duration: 01:28Published
Assam govt to give free COVID vaccines to everyone from 18-45 years [Video]

Assam govt to give free COVID vaccines to everyone from 18-45 years

Assam government has procure 2 crore vaccine from Serum Institute of India and Bharat Biotech and will provide free vaccines to everyone from 18 to 45 years of age, informed state Health Minister..

Credit: ANI     Duration: 01:40Published

You Might Like


Covaxin does not contain newborn calf serum, say Bharat Biotech and govt


IndiaTimes - Published

Fact Check: No newborn calf serum in Covaxin, Health Ministry and Bharat Biotech confirm

The final vaccine does not contain newborn calf serum at all as the calf serum is not an ingredient of the final vaccine product, Health Ministry said
DNA - Published

Covaxin does not contain newborn calf serum: Centre busts myths

The indigenously developed Covaxin does not contain newborn calf serum, clarified Centre on Wednesday. The statement came in response to some social media posts which the government said have "twisted..
IndiaTimes - Published

SII, Bharat Biotech seek hike in government price for Covid vaccines

Serum Institute of India (SII) and Bharat Biotech (BB) are seeking higher prices for Covid-19 vaccines from the Centre amid concerns that the cost of Covishield and Covaxin shots in private hospitals..
IndiaTimes - Published

Bharat Biotech says Rs 150 per Covaxin dose to government not sustainable

The vaccine maker has said that it had to invest over Rs 500 crore at risk from its resources for product development, clinical trials, manufacturing.
DNA - Published

Covaxin average price realisation less than Rs 250 per dose: Bharat Biotech


IndiaTimes - Published

CISF takes over security of Bharat Biotech plant


IndiaTimes - Published

CISF takes over security of Covaxin manufacturer Bharat Biotech's Hyderabad campus


IndiaTimes - Published

Covaxin maker Bharat Biotech gets CISF cover of 64 personnel


IndiaTimes - Published

Can person with any allergy take COVID-19 shots? Know what experts say

Bharat Biotech, the manufacturer of the COVID-19 vaccine said that those who have known allergies to any component of Covaxin should not take the jab.
DNA - Published

Committed to data transparency on Covaxin, published 9 papers in 12 months: Bharat Biotech


IndiaTimes - Published

Ocugen to seek emergency nod for Covaxin from Health Canada

Bharat Biotech’s US partner Ocugen said it will be seeking an emergency use nod for India’s first indigenously developed Covid-19 vaccine Covaxin from the Canadian health authorities. The company..
IndiaTimes - Published

Ocugen to seek full approval for Covaxin in US via BLA instead of EUA

Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application..
IndiaTimes - Published

Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for Canada

Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application..
IndiaTimes - Published

Brazil regulator grants GMP certification to Bharat Biotech's Covaxin facilities

Less than a week after Brazil’s health regulator green-lighted the “exceptional import” of 4 million doses of Bharat Biotech’s Covid-19 jab Covaxin, it has now granted certification of Good..
IndiaTimes - Published

Bharat Biotech to conduct Covaxin Phase-4 trials to check real-world effectiveness


IndiaTimes - Published

Bharat Biotech exec, researcher spar over vaccine-efficacy study


IndiaTimes - Published

Covishield produces more antibodies than Covaxin, finds study

Covishield, from the Oxford-AstraZeneca stable, is manufactured by the Serum Institute of India in Pune. Covaxin is the indigenously manufactured vaccine by Hyderabad-based Bharat Biotech in..
IndiaTimes - Published

Good immune response from Covishield & Covaxin: Study

A ‘real-world’ study of vaccinated healthcare workers has found Covishield and Covaxin could produce a high immune response in up to 95% recipients and prevent serious disease in those infected..
IndiaTimes - Published

Brazil health regulator finally gives green signal for Covaxin imports

In a move that paves the way for exports of indigenously developed Covid-19 vaccine Covaxin to Brazil, its health regulator Anvisa (Agência Nacional de Vigilância Sanitária) has finally given the..
IndiaTimes - Published

After US market, Bharat Biotech ties up with Ocugen for Covaxin sale in Canada


IndiaTimes - Published

Covid-19: Government plans 1 crore daily vaccines from middle of July

The Centre plans to ramp up vaccination against Covid-19 on a “mission mode”, targeting an average of around 1 crore inoculations per day from around mid-July or August as vaccine supplies are..
IndiaTimes - Published

Bharat Biotech to ramp up production of Covaxin to 10-12 crore doses by July-end: Dr NK Arora

With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the..
IndiaTimes - Published

2.8 crore doses of Covaxin supplied so far, says Centre

Bharat Biotech has supplied almost 2.8 crore doses of Covaxin to the Centre as of May 28 morning, a PIB release said on Friday. Of these, about 2.2 crore doses, including wastage, have been consumed by..
IndiaTimes - Published

Centre creating 'artificial scarcity' of Covid vaccines to benefit Bharat Biotech, SII: AAP


IndiaTimes - Published

Covaxin puzzle: 6 crore shots ready, 2 crore given. Where are the rest?

The mismatch between reported production numbers of Covid vaccines in India and the level of daily vaccination seems particularly acute in the case of Covaxin. Official data shows 2.1 crore doses of..
IndiaTimes - Published

Bharat Biotech files 2 new GMP certification requests with Brazil's Anvisa for Covaxin


IndiaTimes - Published

ICMR to examine effectiveness of AstraZeneca's Covishield and Bharat Biotech's Covaxin


IndiaTimes - Published

Covaxin reached 30 cities in 30 days, says Bharat Biotech's co-founder


IndiaTimes - Published

Bharat Biotech likely to get a pre-qualification approval from WHO by August

​​The company has informed the government that it is currently in the process of submitting documents, particularly regarding validation of one of its manufacturing facilities. It is also..
IndiaTimes - Published

Bharat Biotech needs to give more information for emergency use listing, says WHO


IndiaTimes - Published

WHO says 'more information' required from Bharat Biotech for emergency use listing of Covaxin


IndiaTimes - Published

Bharat Biotech submitted 90% of documentation to WHO for emergency use listing for Covaxin: Sources


IndiaTimes - Published

Paediatric trials of Covaxin may begin in June: Bharat Biotech official

Bharath Biotech may start clinical trials of its Covid-19 vaccine Covaxin on children from June, a senior official of the vaccine-maker has said. The efficacy of the jab can be improved up to 100%..
IndiaTimes - Published Also reported by •DNA

Bharat Biotech applies for WHO approval, pre-submission meeting soon

It will have to now go through 3 more stages--pre-submission meeting, dossier accepted for review and the final status of assessment.
DNA - Published

Government steps in to expedite WHO approval for Covaxin

ToI has learnt that foreign secretary Harsh Shringla will hold a meeting with Bharat Biotech, the manufacturer of Covaxin, on Monday to expedite the process of WHO approval for the indigenously..
IndiaTimes - Published

Exclusive: Bharat Biotech's Suchitra Ella confident on vaccine production commitments

She assured that Covaxin was proved to be neutralizing the double mutant variant found in India and other variants found abroad.
DNA - Published

Bharat Biotech targets 1billion/year doses by 2021-end


IndiaTimes - Published

Bharat Biotech to ramp up Covaxin production to 1 billion doses a year

Hyderabad-based Bharat Biotech is planning to scale up the production capacity of its indigenously-developed Covid vaccine — Covaxin — to 1 billion doses per annum by the fourth quarter of 2021.A..
IndiaTimes - Published

Covaxin trial for 2-18 yrs age group to begin in 10-12 days, govt says

Trial of Bharat Biotech's Covaxin in the 2-18 years age group is likely to begin in the next 10-12 days., a govt official said. The vaccine received DCGI approval for the trials last week. 1.8% of..
IndiaTimes - Published

Covaxin effective against India, UK coronavirus strains: Bharat Biotech


IndiaTimes - Published

Covaxin effectively neutralises all key emerging variants, says study published in Oxford journal

Indigenous Covid-19 vaccine Covaxin has been able to neutralise all key emerging variants, including the double mutant B.1.617 and B.1.1.7, which was first identified in India and the UK, its developer..
IndiaTimes - Published

Get Bharat Biotech to share vaccine manufacturing tech with other WHO prequalified pharma cos: Ghulam Nabi Azad


IndiaTimes - Published

Covaxin dispatched to various states like Gujarat, Assam: Bharat Biotech


IndiaTimes - Published

Centre, Bharat Biotech willing to invite other companies to scale up Covaxin production

Amid the reports of coronavirus vaccine shortage from various states, the Central government and Hyderabad-based Bharat Biotech are willing to invite other companies which want to produce COVAXIN in a..
IndiaTimes - Published

Bharat Biotech's 50 employees test COVID-19 positive, Joint MD's tweet evokes mixed response on Twitter

Suchitra Ella's tweet evoked mixed response from netizens with some questioning the effectiveness while others asked why the staff was not vaccinated.
DNA - Published

DGCI gives nod for Covaxin Phase II/III trials on 2-18 year olds

The Indian drugs regulator, the Drugs Controller General of India (DCGI) has granted its approval to indigenously developed Covid-19 vaccine Covaxin’s developer Bharat Biotech for conducting Phase..
IndiaTimes - Published

50 employees of Bharat Biotech test Covid-19 positive; Joint MD's tweet draws bouquets and brickbats


IndiaTimes - Published

Serum says will raise monthly production to 10 crore doses by August, Bharat Biotech promises 7.8 crore


IndiaTimes - Published

Covid-19: DCGI approves phase 2, 3 clinical trials of Covaxin on children aged 2 to 18 years

The Drugs Controller General of India (DCGI) approved phase 2 and 3 clinical trials of Bharat Biotech's Covaxin vaccine for the age group of 2 to 18 years, the ministry of health and family welfare..
IndiaTimes - Published


 Page 1  〉